

# Elena Ongaro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7443466/publications.pdf>

Version: 2024-02-01

47  
papers

1,210  
citations

471509  
17  
h-index

377865  
34  
g-index

48  
all docs

48  
docs citations

48  
times ranked

2438  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic role of visceral fat for overall survival in metastatic colorectal cancer: A pilot study. <i>Clinical Nutrition</i> , 2021, 40, 286-294.	5.0	17
2	Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer. <i>Cancers</i> , 2021, 13, 3504.	3.7	5
3	NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. <i>Cells</i> , 2021, 10, 2034.	4.1	20
4	Determinants of choice in offering drug holidays during first-line therapy for metastatic colorectal cancer. <i>Future Oncology</i> , 2020, 16, 2645-2660.	2.4	1
5	TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. <i>Cancers</i> , 2020, 12, 2049.	3.7	11
6	416P A novel prognostic tool based on lymphocyte ratios in patients with stage III colon cancer. <i>Annals of Oncology</i> , 2020, 31, S418.	1.2	0
7	Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3314-3324.	1.6	139
8	P-266 LDH levels as predictors of efficacy in second-line treatment for metastatic gastric cancer: The LINE study. <i>Annals of Oncology</i> , 2020, 31, S176-S177.	1.2	0
9	Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. <i>Gastric Cancer</i> , 2020, 23, 1064-1074.	5.3	5
10	The MIMIC Study: Prognostic Role and Cutoff Definition of Monocyte-to-Lymphocyte Ratio and Lactate Dehydrogenase Levels in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2020, 25, 661-668.	3.7	21
11	P-246 Taxane cross-resistance: An exploratory analysis of second-line chemotherapy for metastatic gastric cancer. <i>Annals of Oncology</i> , 2020, 31, S170.	1.2	0
12	A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the "BRAF BeCool"™ study. <i>European Journal of Cancer</i> , 2019, 118, 121-130.	2.8	51
13	Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component. <i>Clinical Colorectal Cancer</i> , 2019, 18, 116-124.	2.3	7
14	Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019, 4, e000489.	4.5	14
15	The <scp>IMPACT</scp> study: early loss of skeletal muscle mass in advanced pancreatic cancer patients. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 368-377.	7.3	61
16	Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. <i>ESMO Open</i> , 2019, 4, e000496.	4.5	3
17	Efficacy of retreatment with anti-EGFRs in mCRC is not predictable by clinical factors related to prior lines of therapy: A multi-institutional analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3540-3540.	1.6	0
18	Comparison of primary breast cancer and paired metastases: biomarkers discordance influence on outcome and therapy. <i>Future Oncology</i> , 2018, 14, 849-859.	2.4	14

#	ARTICLE	IF	CITATIONS
19	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	7.0	76
20	A retrospective study of trifluridine/tipiracil in pretreated metastatic colorectal cancer patients in clinical practice. <i>Colorectal Cancer</i> , 2018, 7, CRC01.	0.8	3
21	The Winding Roadmap of Biomarkers toward Clinic: Lessons from Predictors of Resistance to Anti-EGFRs in Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2298.	4.1	4
22	Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver limited metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e15511-e15511.	1.6	0
23	The immune-profile of mismatch repair deficient (dMMR) colorectal cancers (CRCs) differs according to primary tumor sidedness.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15593-e15593.	1.6	0
24	Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. <i>Pharmacogenomics Journal</i> , 2017, 17, 258-264.	2.0	79
25	Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 365-374.	3.1	27
26	Sarcopenia in gastric cancer: when the loss costs too much. <i>Gastric Cancer</i> , 2017, 20, 563-572.	5.3	47
27	Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 709-721.	3.1	85
28	Immunotherapy for gastric cancers: emerging role and future perspectives. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 609-619.	3.1	33
29	Breakthrough Cancer Pain: Preliminary Data of The Italian Oncologic Pain Multisetting Multicentric Survey (IOPS-MS). <i>Advances in Therapy</i> , 2017, 34, 120-135.	2.9	19
30	Molecular classifications of gastric cancers: Novel insights and possible future applications. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 194.	2.0	46
31	HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. <i>Oncotarget</i> , 2016, 7, 69060-69074.	1.8	29
32	The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?. <i>Targeted Oncology</i> , 2016, 11, 593-603.	3.6	14
33	HER2 loss in HER2â€positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. <i>International Journal of Cancer</i> , 2016, 139, 2859-2864.	5.1	94
34	Apatinib for gastric cancer: are we moving the antiangiogenic strategy any forward?. <i>Translational Cancer Research</i> , 2016, 5, S765-S771.	1.0	2
35	TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS3629-TPS3629.	1.6	0
36	2027 KRAS status and risk of venous thromboembolic events in patients with metastatic colorectal cancer: A case-control study. <i>European Journal of Cancer</i> , 2015, 51, S337.	2.8	0

#	ARTICLE	IF	CITATIONS
37	Timing and extent of response in colorectal cancer: critical review of current data and implication for future trials. <i>Oncotarget</i> , 2015, 6, 28716-28730.	1.8	14
38	Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 165-178.	4.4	26
39	Prognostic significance of <i>K-Ras</i> mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015, 6, 31604-31612.	1.8	30
40	Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the progression of colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e14519-e14519.	1.6	0
41	Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2015, 33, e22075-e22075.	1.6	0
42	The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey. <i>Expert Opinion on Investigational Drugs</i> , 2014, 23, 925-942.	4.1	32
43	Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS3664-TPS3664.	1.6	2
44	Clinical advances in the development of novel VEGFR2 inhibitors. <i>Annals of Translational Medicine</i> , 2014, 2, 123.	1.7	121
45	Differences in hormonal receptor status and Ki67 expression between primary breast cancer and metastasis: Is variation related to previous therapy?. <i>Journal of Clinical Oncology</i> , 2014, 32, e22006-e22006.	1.6	0
46	Critical Appraisal of Ramucirumab (IMC-1121B) for Cancer Treatment: From Benchside to Clinical Use. <i>Drugs</i> , 2013, 73, 2003-2015.	10.9	48
47	Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. <i>World Journal of Gastroenterology</i> , 2013, 19, 8474.	3.3	9